Yahoo
OTC Markets OTCPK - Delayed Quote USD

BioElectronics Corporation (BIEL)

0.0003 +0.0001 (+20.00%)
At close: November 5 at 4:00:00 PM EST
Chart Range Bar
Loading chart for BIEL
  • Previous Close 0.0003
  • Open 0.0003
  • Bid 0.0002 x 38467524500
  • Ask 0.0003 x 896565400
  • Day's Range 0.0003 - 0.0003
  • 52 Week Range 0.0002 - 0.0014
  • Volume 2,000,016
  • Avg. Volume 6,594,800
  • Market Cap (intraday) 7.412M
  • Beta (5Y Monthly) 2.20
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions. It sells its products to wholesale distributors, hospitals and clinics, and consumers. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.

www.bielcorp.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BIEL
25.00%
S&P 500 (^GSPC)
7.76%

1-Year Return

BIEL
14.29%
S&P 500 (^GSPC)
9.77%

3-Year Return

BIEL
0.00%
S&P 500 (^GSPC)
68.96%

5-Year Return

BIEL
78.57%
S&P 500 (^GSPC)
57.04%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -18.01%

  • Return on Assets (ttm)

    -33.67%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.61M

  • Net Income Avi to Common (ttm)

    -289.82k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    925

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -554.29k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: